Table 6. Antibiotic sensitivity of Listeria monocytogenes strains obtained from human (n=11).
| Antibiotics | Strains obtained from human | Sensitivity of the isolates (n, %)1) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SMFM-CI-1 | SMFM-CI-2 | SMFM-CI-3 | SMFM-CI-4 | SMFM-CI-5 | SMFM-CI-6 | SMFM-CI-7 | SMFM-CI-8 | SMFM-CI-9 | SMFM-CI-10 | SMFM-CI-11 | Susceptible | Intermediate | Resistant | ||
| Gentamycin | S | S | S | S | S | S | S | S | S | S | S | 11 (100) |
|||
| Bacitracin | S | R | S | R | S | S | R | S | S | S | S | 8 (72.7) |
3 (27.3) |
||
| Penicillin G | R | R | R | R | R | R | R | R | R | R | R | 11 (100) |
|||
| Tetracycline | S | S | R | S | R | R | S | S | S | S | S | 8 (72.7) |
3 (27.3) |
||
| Spectinomycin | S | S | S | S | S | S | S | S | S | S | S | 11 (100) |
|||
| Kanamycin | S | S | S | S | S | S | S | S | S | S | S | 11 (100) |
|||
| Erythromycin | S | I | S | R | S | S | R | S | S | S | S | 8 (72.7) |
1 (9.1) |
2 (18.2) |
|
| Tigecycline | S | S | S | S | S | S | S | S | S | S | S | 11 (100) |
|||
| Ampicillin | S | R | S | R | S | S | R | S | S | S | S | 8 (72.7) |
3 (27.3) |
||
| Streptomycin | I | R | R | R | R | R | R | S | R | I | I | 1 (9.1) |
3 (27.3) |
7 (63.6) |
|
| Chloramphenicol | S | S | S | S | S | S | S | S | S | S | S | 11 (100) |
|||
| Rifampicin | S | R | S | R | S | S | R | S | S | S | S | 8 (72.7) |
3 (27.3) |
||
| Susceptible (n, %) |
10 (83.3) |
6 (50) |
9 (75) |
6 (50) |
9 (75) |
9 (75) |
6 (50) |
11 (91.7) |
10 (83.3) |
10 (83.3) |
10 (83.3) |
||||
| Intermediate (n, %) |
1 (8.3) |
1 (8.3) |
1 (8.3) |
1 (8.3) |
|||||||||||
| Resistant (n, %) |
1 (8.3) |
5 (41.7) |
3 (25) |
6 (50) |
3 (25) |
3 (25) |
6 (50) |
1 (8.3) |
2 (16.7) |
1 (8.3) |
1 (8.3) |
||||
1) According to CLSI guidelines using the breakpoints of Staphylococcus species resistance because no resistance criteria exist for Listeria susceptibility testing in the CLSI guidelines (Byrne et al., 2016).